SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Dr. Reddy's Laboratories Ltd. and Certain Officers and Directors

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky, LLP announces that it has commenced an investigation of Dr. Reddy's Laboratories Ltd. ("RDY" or the "Company") RDY concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On November 5, 2015, U.S. regulators sent "warning letters" to RDY in reference to insufficient quality controls at three of the Company's manufacturing plants. These plants produce drugs for cancer and other diseases. The Company stated this FDA warning would result in no U.S. approvals for any drugs made at these plants until all issues are resolved. The manufacturing plants make up approximately 10 to 12 percent of RDY's sales. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/dr-reddys-laboratories-rdy

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160303005958/en/